Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Ten-year recovery outcomes for clients with co-occurring schizophrenia and substance use disorders.

Drake RE, McHugo GJ, Xie H, Fox M, Packard J, Helmstetter B.

Schizophr Bull. 2006 Jul;32(3):464-73. Epub 2006 Mar 8.

2.

Three-year recovery outcomes for long-term patients with co-occurring schizophrenic and substance use disorders.

Xie H, McHugo GJ, Helmstetter BS, Drake RE.

Schizophr Res. 2005 Jun 15;75(2-3):337-48.

PMID:
15885525
3.

Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders.

Brunette MF, Noordsy DL, Xie H, Drake RE.

Psychiatr Serv. 2003 Oct;54(10):1395-401.

PMID:
14557527
4.

Longitudinal Course of Clients With Co-occurring Schizophrenia-Spectrum and Substance Use Disorders in Urban Mental Health Centers: A 7-Year Prospective Study.

Drake RE, Luciano AE, Mueser KT, Covell NH, Essock SM, Xie H, McHugo GJ.

Schizophr Bull. 2016 Jan;42(1):202-11. doi: 10.1093/schbul/sbv110. Epub 2015 Aug 19.

5.

A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness.

Bellack AS, Bennett ME, Gearon JS, Brown CH, Yang Y.

Arch Gen Psychiatry. 2006 Apr;63(4):426-32.

PMID:
16585472
6.

Substance abuse relapse in a ten-year prospective follow-up of clients with mental and substance use disorders.

Xie H, McHugo GJ, Fox MB, Drake RE.

Psychiatr Serv. 2005 Oct;56(10):1282-7.

PMID:
16215196
7.

Longitudinal assessment of inpatient use and functioning of seriously mentally ill veterans with and without co-occurring substance use disorders.

Blow FC, Barry KL, BootsMiller BJ, Copeland LA, McCormick R, Visnic S.

J Psychiatr Res. 1998 Sep-Oct;32(5):311-9.

PMID:
9789210
8.

The impact of substance use disorders on the course of schizophrenia--a 15-year follow-up study: dual diagnosis over 15 years.

Schmidt LM, Hesse M, Lykke J.

Schizophr Res. 2011 Aug;130(1-3):228-33. doi: 10.1016/j.schres.2011.04.011. Epub 2011 May 18.

PMID:
21592731
9.

Three-year outcomes of long-term patients with co-occurring bipolar and substance use disorders.

Drake RE, Xie H, McHugo GJ, Shumway M.

Biol Psychiatry. 2004 Nov 15;56(10):749-56.

PMID:
15556119
10.

A randomized controlled trial of family intervention for co-occurring substance use and severe psychiatric disorders.

Mueser KT, Glynn SM, Cather C, Xie H, Zarate R, Smith LF, Clark RE, Gottlieb JD, Wolfe R, Feldman J.

Schizophr Bull. 2013 May;39(3):658-72. doi: 10.1093/schbul/sbr203. Epub 2012 Jan 26.

11.

Consumer satisfaction with inpatient psychiatric treatment among persons with severe mental illness.

Hackman A, Brown C, Yang Y, Goldberg R, Kreyenbuhl J, Lucksted A, Wohlheiter K, Dixon L.

Community Ment Health J. 2007 Dec;43(6):551-64. Epub 2007 Jul 20.

PMID:
17641972
12.

The burden of depressive symptoms in the long-term treatment of patients with schizophrenia.

Conley RR, Ascher-Svanum H, Zhu B, Faries DE, Kinon BJ.

Schizophr Res. 2007 Feb;90(1-3):186-97. Epub 2006 Nov 15.

13.
14.

[Cannabis and schizophrenia: demographic and clinical correlates].

Dervaux A, Laqueille X, Bourdel MC, Leborgne MH, Olié JP, Lôo H, Krebs MO.

Encephale. 2003 Jan-Feb;29(1):11-7. French.

PMID:
12640322
15.

A Qualitative Study of Client-Clinician Text Exchanges in a Mobile Health Intervention for Individuals With Psychotic Disorders and Substance Use.

Aschbrenner KA, Naslund JA, Gill LE, Bartels SJ, Ben-Zeev D.

J Dual Diagn. 2016;12(1):63-71. doi: 10.1080/15504263.2016.1145312.

16.

Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorders: I. Predictive value of disorder-related factors.

Ritsner MS, Lisker A, Arbitman M.

Qual Life Res. 2012 Jun;21(5):837-47. doi: 10.1007/s11136-011-9988-2. Epub 2011 Sep 13.

PMID:
21912845
17.

Five-year outcome of first-episode psychosis before and after the implementation of a modified assertive community treatment programme.

Bodén R, Sundström J, Lindström E, Wieselgren IM, Lindström L.

Soc Psychiatry Psychiatr Epidemiol. 2010 Jun;45(6):665-74. doi: 10.1007/s00127-009-0108-3. Epub 2009 Aug 4.

PMID:
19652896
18.

Naturalistic follow-up of co-morbid substance use in schizophrenia: the West London first-episode study.

Harrison I, Joyce EM, Mutsatsa SH, Hutton SB, Huddy V, Kapasi M, Barnes TR.

Psychol Med. 2008 Jan;38(1):79-88. Epub 2007 May 29.

19.

Comorbidity of severe psychotic disorders with measures of substance use.

Hartz SM, Pato CN, Medeiros H, Cavazos-Rehg P, Sobell JL, Knowles JA, Bierut LJ, Pato MT; Genomic Psychiatry Cohort Consortium..

JAMA Psychiatry. 2014 Mar;71(3):248-54. doi: 10.1001/jamapsychiatry.2013.3726.

20.

A 12-month prospective follow-up study of patients with schizophrenia-spectrum disorders and substance abuse: changes in psychiatric symptoms and substance use.

Margolese HC, Carlos Negrete J, Tempier R, Gill K.

Schizophr Res. 2006 Mar;83(1):65-75. Epub 2006 Feb 7.

PMID:
16460917

Supplemental Content

Support Center